1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
YD Bio Limited Warrants

YD Bio Limited Warrants

YDESW
YD Bio Limited WarrantsUS flagNASDAQ Global Select
0.29
USD
+0.03
- -
944,689.00Market Cap
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
- -
- -
Book Value per Share
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
Sales/Revenue/Turnover
- -
1
1
Operating Margin (%)
-2.03
-286.55
-882.74
Depreciation Expense
- -
- -
- -
Net Income, GAAP
- -
-1
-8
Effective Tax Rate (%)
23.17
- -
- -
Profit Margin (%)
3.87
-276.58
-1,392.61
Working Capital
- -
3
8
LT Debt
- -
- -
- -
Total Equity
- -
7
-3
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-143.33%
Free Cash Flow
- -
- -
94.42%
Net Income, GAAP
- -
- -
488.8%
Sales/Revenue/Turnover
- -
- -
16.94%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Ethan Shen
Full Time Employees
4
Sector
Healthcare
Industry
Biotechnology
Address
No. 3, Xingnan St. Taipei TP Taiwan, Province of China 115001
IPO Date
Aug 29, 2025
CIK
0002011674
Website
ydesgroup.com
Similar Companies
Purple Biotech Ltd. (PPBT)
UCB S.A. (UCB.BR)
Hvsen Biotechnology Co., Ltd. (300871.SZ)
MultiCell Technologies, Inc. (MCET)
CSL Limited (CMXHF)
Adagene Inc. (ADAG)
Business
YD Bio Limited (Nasdaq: YDES; YDESW), a biotechnology company founded in 2013 and headquartered in Taipei, Taiwan, focuses on blood-based cancer detection through non-invasive DNA methylation analysis for early detection, treatment monitoring, and recurrence tracking of cancers including pancreatic and breast; develops stem cell- and exosome-based therapeutics such as limbal stem cell-derived exosomes for regenerative medicine targeting ocular surface conditions, dry eye disease, glaucoma, and corneal repair; supplies high-quality clinical trial drugs and nutritional supplements to pharmaceutical companies including Novartis; and offers innovative ophthalmic products comprising contact lenses and artificial tears for dry eye care. The company serves healthcare providers, hospitals, insurance companies, pharmacies, and optometrists across the United States, Europe, Asia-Pacific, and Taiwan through research collaborations, licensing agreements, and distribution channels. In August 2025, YD Bio completed a business combination with Breeze Holdings Acquisition Corp and a concurrent PIPE financing yielding $13.2 million in gross proceeds to fund operations and innovation; listed its ordinary shares and warrants on Nasdaq Global Market under YDES and YDESW; signed an exclusive license on September 30, 2025, for breast cancer detection technology across the U.S., Europe, and Asia-Pacific; obtained licenses from EG BioMed Taiwan for pancreatic cancer detection and established a U.S. laboratory; secured patent and technology authorizations from 3D Global Biotech for corneal mesenchymal stem cell and exosome applications in eye diseases; and announced U.S. ophthalmology market entry in November 2025 while advancing LSC exosome therapeutics.